Quality and Innovation

Our aim is to make the name Béres synonymous with premium quality in all product categories.

The key principle underlying our approach to quality is that all Béres products should be characterised by the highest level of quality and safety attainable.

In terms of the manufacturing of our products, we observe the requirements of Good Manufacturing Practice (GMP) and follow strict guidelines to assure the conditions needed to manufacture products of the highest quality.

Besides observing the HACCP principles and guidelines, we have set up our own system of quality assurance requirements for our dietary supplements.

We work with qualified suppliers and controlled raw materials in accordance with local and EU regulations.

We have sophisticated instruments available for comprehensive analysis and testing, which allow us to verify the content of incoming raw materials and finished products, regularly test for the presence of contaminants, assess microbiological purity.

More than 60 highly qualified professionals work in the Quality Control Department.

QUALITY STANDARDS

  • GMP (as applicable to medicinal-product manufacturers) 
  • HACCP (Hazard Analysis and Critical Control Points) guidelines for food supplement production
  • EU Medicines Legislation
  • EU Food Supplement Directive 2002/46/EC
  • EU Medical Device Regulation MDR 2017/745

OUR PRODUCTION TECHNOLOGIES

  • dry granulation (compaction),
  • homogenization of powders,
  • tableting by direct compression (no wet granulation),
  • film-coating,
  • hard gel capsule filling,
  • liquid filling,
  • gummy vitamin production,
  • automated packaging,
  • serialization.

Our entire product manufacturing process – from procurement to delivery of the finished product – is characterised by full compliance with GMP and/or HACCP (Hazard Analysis and Critical Control Points) regulations. 

Béres products are produced in a proprietary factory in Szolnok, with a clean-floor area of 4,956 m2.

In 2020, our production output exceeded 20 million boxes, 800 million tablets and 212 thousand litres of Béres Drops. 

For this ever-increasing volume of production, continuous developments are needed. A HUF 7 billion investment was launched in the autumn of 2019, which is expected to be completed in 2021. As part of the development, we will increase the production area at the factory, expand and modernise production technology, and acquire additional equipment for our quality control and research-and-development laboratories. 

Our professional R&D base employs highly qualified, experienced professionals.  

A dedicated Innovation Group (acting as a centre of excellence) ensures continuous development and innovation based on the latest scientific findings and consumer insights.

We monitor our products throughout their entire lifecycle and comply with GVP regulations for medicines and medical devices.